Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities

NEXT STORY
Apexigen to Participate in Upcoming Investor Conferences
PREV STORY
iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

NATIONAL SUMMER LEARNING ASSOCIATION APPLAUDS CONGRESS FOR WORKING TOGETHER TO APPROVE $121.9 BILLION FOR K-12 ECONOMIC SUPPORT WITH SET ASIDES FOR SUMMER LEARNING AND OUT-OF-SCHOOL TIME PROGRAMS

author_avatar
NASDAQ Market News

Positive Interim Results of CHOICE-01 Study Evaluating Coherus’ and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer

author_avatar
NASDAQ Market News

Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting

Basel, Switzerland, June 6, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that ...

author_avatar
NASDAQ Market News